Xenetic Biosciences' Q1 royalty revenue rises, net loss narrows

ReutersMay 13, 2026 12:13 PM

View all comments（0）



Overview

US biopharma firm's Q1 2026 royalty revenue rose 36% yr/yr, driven by higher Takeda payments
Net loss for Q1 2026 narrowed 49% from prior year period
Company ended Q1 2026 with $7.3 mln in cash, continues to review strategic alternatives

Result Drivers

ROYALTY REVENUE GROWTH - Q1 royalty revenue rose 36% yr/yr, mainly due to increased payments from Takeda under a sublicense agreement
LOWER R&D COSTS - Research and development expenses fell 25% yr/yr, mainly due to reduced preclinical and exploratory study costs, partially offset by higher manufacturing development spending
REDUCED PERSONNEL AND SHARE-BASED COSTS - General and administrative expenses declined 1.4%, mainly due to lower personnel and share-based expenses, mostly offset by higher legal costs from the strategic review process

Company press release: ID:nACS0nvBqa

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q1 Net Income		-$500,000

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

Commenting Guidelines

Recommended Articles

PPI Report April 2026: How Inflation Data Is Moving HIMS, CEG, and PLUG Stock Today

TradingKey - Wall Street is navigating a two-day inflation gauntlet. Tuesday's CPI print for April arrived hotter than expected, rattling equity markets from telehealth to nuclear energy. Wednesday morning brings the Producer Price Index (PPI) for April — and if today's Consumer Price Index is any g

Will Nvidia Stock Pop on May 20 Earnings? How to Position Now

TradingKey - The results for Nvidia (NVDA) will be announced on May 20 after the market closes, and this report is very important for more than just one stock symbol.

Will US April PPI Ease Inflationary Pressure? Short-Term Forecasts for US Stocks, Dollar and Gold

TradingKey - The U.S. is set to release April PPI data at 8:30 AM ET on May 13. Markets widely expect the U.S. April PPI to continue its upward trend, with the consensus pointing to a year-on-year growth rate of 4.9%, up from 4.0% in March. If realized, concerns regarding the upstream transmission of inflationary pressures will further intensify.

Samsung’s Largest Strike in History: Can SK Hynix and Micron Sit Back and Reap the Benefits?

TradingKey - On May 21, 61,000 union members at Samsung Electronics will launch an 18-day general strike, following a 93.1% approval vote. Government mediation between labor and management has collapsed.

Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

TradingKey - Cerebras Systems (CBRS) IPO prices May 13–14 at $125–$135/share. $26–$27B valuation, 20x oversubscribed, $510M revenue, 47% net margin, OpenAI 750MW deal. Everything you need to know.

Featured Tools